Cytosorbents Corp 8-K Summary: Material Definitive Agreement
Business Context and Reporting Period
Cytosorbents Corporation (CTSO) filed this Form 8-K on January 19, 2022, to disclose the entry into a material definitive agreement. The Company, along with its wholly owned subsidiary CytoSorbents Medical, Inc., amended its existing Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank.
Key Financial Metrics and Debt Structure
This filing details a new credit facility rather than reporting period-end financial results. Key terms of the Fourth Amendment include:
- Total Facility Size: Up to $15 million available in three tranches of $5 million each.
- Availability Period: Funds may be drawn at the Company's discretion between January 19, 2022, and December 31, 2022, or until an Event of Default.
- Interest Rate: Floating rate based on the Index Rate plus 1.25%, subject to a cap of 8.00%.
- Repayment Terms: Interest-only payments until an amortization date of January 1, 2024 (or July 1, 2024, if an extension event occurs), followed by equal monthly principal and interest payments.
- Maturity Date: Extended to December 1, 2025.
- Fees: A non-refundable commitment fee of $18,750 was paid on the amendment date.
Material Changes and Success Fees
The agreement introduces a contingent "Success Fee" structure tied to the Company's stock price performance upon drawing down specific tranches:
- Tranche 1 ($5M): 1% fee ($50,000) if stock price exceeds $8 for five consecutive trading days.
- Tranche 2 ($5M): 1.5% fee ($75,000) if stock price exceeds $10 for five consecutive trading days.
- Tranche 3 ($5M): 2% fee ($100,000) if stock price exceeds $12 for five consecutive trading days.
Success fees may be paid in cash or common stock at the Borrower's discretion. The obligation to pay these fees terminates five years after the funding date of the last loan but survives prepayment or termination of the Loan Agreement.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, revenue outlook, or management commentary on operational performance. The primary risk disclosed relates to the contingent equity dilution or cash outflow associated with the Success Fees if the Company draws down the full $15 million and meets the specified stock price thresholds.
Investor Verification Checklist
- Verify the Company's current cash position to determine the likelihood of drawing down the new $15 million facility.
- Monitor the stock price relative to the $8, $10, and $12 thresholds to assess potential future Success Fee obligations.
- Review the definition of "Event of Default" in the attached Exhibit 10.1 to understand conditions that could restrict access to funds.
- Confirm whether the Company intends to pay Success Fees in cash or stock, as this impacts future dilution.